FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237289321> ?p ?o ?g. }

• W4237289321 abstract "Abstract Background : Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder forming hamartomas throughout the body. Facial angiofibromas (FAs) occur in 75% of TSC patients, which are often enlarged, impairing the appearance of the face, and reducing the patient's quality of life (QOL). The aim of this study was to characterize the impact of topical sirolimus treatment on the health-related QOL in patients with FA associated with TSC. Methods : We investigated a total of 33 patients who received sirolimus gel treatment for FA associated with TSC and assessed the changes in the health-related QOL using the Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey. SF-36 surveys were performed before and after three months of treatment. The conditions of the patients after using the sirolimus gel were categorized into the following three categories: improved, unchanged, and aggravated. Adverse events were investigated using the CTCAE v5.0-JCOG. Results : The median age of the patients was 25 (range 14-55) years. After 3 months of sirolimus gel treatment, three scale scores of the SF-36, vitality (VT), social function (SF), and mental health (MH), were significantly improved compared to before the treatment. The VT and SF in patients who had improved FA were significantly better than those in the other patients. There were no significant differences in any scale scores between patients with and without adverse events at three months after the initiation of sirolimus gel treatment. Conclusions : This is the first report regarding improved health-related quality of life in patients treated with sirolimus gel for FA associated with TSC by using the SF-36. The three scale scores associated with mental health were significantly improved compared to before the treatment. The health-related QOL in patients receiving sirolimus gel treatment is more strongly affected by the treatment efficacy than adverse events. Mini-abstract Sirolimus gel treatment improves the health-related QOL in patients with FA associated with TSC." @default.
• W4237289321 created "2022-05-12" @default.
• W4237289321 creator A5026942255 @default.
• W4237289321 creator A5039271211 @default.
• W4237289321 creator A5041040200 @default.
• W4237289321 creator A5047246036 @default.
• W4237289321 creator A5068724534 @default.
• W4237289321 creator A5071471970 @default.
• W4237289321 creator A5082602379 @default.
• W4237289321 date "2020-05-21" @default.
• W4237289321 modified "2023-09-23" @default.
• W4237289321 title "Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex." @default.
• W4237289321 doi "https://doi.org/10.21203/rs.3.rs-20090/v2" @default.
• W4237289321 hasPublicationYear "2020" @default.
• W4237289321 type Work @default.
• W4237289321 citedByCount "0" @default.
• W4237289321 crossrefType "posted-content" @default.
• W4237289321 hasAuthorship W4237289321A5026942255 @default.
• W4237289321 hasAuthorship W4237289321A5039271211 @default.
• W4237289321 hasAuthorship W4237289321A5041040200 @default.
• W4237289321 hasAuthorship W4237289321A5047246036 @default.
• W4237289321 hasAuthorship W4237289321A5068724534 @default.
• W4237289321 hasAuthorship W4237289321A5071471970 @default.
• W4237289321 hasAuthorship W4237289321A5082602379 @default.
• W4237289321 hasBestOaLocation W42372893211 @default.
• W4237289321 hasConcept C126322002 @default.
• W4237289321 hasConcept C141071460 @default.
• W4237289321 hasConcept C142724271 @default.
• W4237289321 hasConcept C159110408 @default.
• W4237289321 hasConcept C16005928 @default.
• W4237289321 hasConcept C197934379 @default.
• W4237289321 hasConcept C2777921159 @default.
• W4237289321 hasConcept C2778980267 @default.
• W4237289321 hasConcept C2779951463 @default.
• W4237289321 hasConcept C2781060204 @default.
• W4237289321 hasConcept C71924100 @default.
• W4237289321 hasConceptScore W4237289321C126322002 @default.
• W4237289321 hasConceptScore W4237289321C141071460 @default.
• W4237289321 hasConceptScore W4237289321C142724271 @default.
• W4237289321 hasConceptScore W4237289321C159110408 @default.
• W4237289321 hasConceptScore W4237289321C16005928 @default.
• W4237289321 hasConceptScore W4237289321C197934379 @default.
• W4237289321 hasConceptScore W4237289321C2777921159 @default.
• W4237289321 hasConceptScore W4237289321C2778980267 @default.
• W4237289321 hasConceptScore W4237289321C2779951463 @default.
• W4237289321 hasConceptScore W4237289321C2781060204 @default.
• W4237289321 hasConceptScore W4237289321C71924100 @default.
• W4237289321 hasLocation W42372893211 @default.
• W4237289321 hasLocation W42372893212 @default.
• W4237289321 hasLocation W42372893213 @default.
• W4237289321 hasOpenAccess W4237289321 @default.
• W4237289321 hasPrimaryLocation W42372893211 @default.
• W4237289321 hasRelatedWork W2113177344 @default.
• W4237289321 hasRelatedWork W2258473985 @default.
• W4237289321 hasRelatedWork W2521224743 @default.
• W4237289321 hasRelatedWork W2742269153 @default.
• W4237289321 hasRelatedWork W2809371718 @default.
• W4237289321 hasRelatedWork W2906007117 @default.
• W4237289321 hasRelatedWork W2937245015 @default.
• W4237289321 hasRelatedWork W3002675225 @default.
• W4237289321 hasRelatedWork W3028936356 @default.
• W4237289321 hasRelatedWork W3148950155 @default.
• W4237289321 isParatext "false" @default.
• W4237289321 isRetracted "false" @default.
• W4237289321 workType "article" @default.